Colexa Biosensor
Colexa Biosensor Ltd is a Nigerian in-vitro diagnostics manufacturer that produces the OnPoint blood glucose monitoring system and locally packages the WHO pre-qualified STANDARD Q HIV rapid diagnostic test, serving the Nigerian Federal Government, state health programs, healthcare providers, and Sub-Saharan African consumer and donor markets.
- Company typePrivate
- Founded2023
- HeadquartersLagos, Nigeria
- Headcount101–250
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Colexa Biosensor does
Colexa Biosensor Ltd is a Nigerian in-vitro diagnostics (IVD) manufacturer founded in 2023 as a subsidiary of Codix Group and headquartered in Lagos, Nigeria. The company operates Sub-Saharan Africa's first IVD factory dedicated to blood glucose meters and strips, producing the OnPoint GH82 Blood Glucose Monitoring System — Nigeria's first locally manufactured glucose monitoring solution — and holds the only authorization in Africa to package the WHO pre-qualified STANDARD Q HIV 1/2 Ab 3-Line Test under a Pre-Qualification Change Notification.
The company's product technology relies on a Glucose Dehydrogenase (GDH-FAD) enzyme-based test strip system requiring 0.5 µL capillary blood samples with results delivered in 6 seconds, alongside features such as auto-coding, dual measurement units (mmol/L and mg/dL), strip ejection, and 7/14/30-day averaging. Its Lagos facility has installed capacity of 3.6 million packs of strips annually, scalable to 10.8 million. A sister Codix Group facility, Codix Bio, was commissioned in May 2025 in Sagamu, Ogun State, with capacity for over 147 million test kits per year for HIV, malaria, and hepatitis B/C under the WHO Health Technology Access Pool (H-TAP) programme. Achieved certifications include ISO 13485:2016 (first in Nigeria for IVD manufacturing), ISO 9001:2015, NAFDAC product registration, and EMSON clinical endorsement.
Colexa generates revenue through hardware sales across three primary channels: government procurement (Federal and state health agencies distributing OnPoint systems across primary healthcare centers, supported by a N10.3 billion FEC-approved medical supply package), direct-to-consumer e-commerce via winwell.ng and physical retail through leading health stores, and B2B supply of WHO pre-qualified HIV RDTs to international donor organizations and Nigeria's National AIDS and STI Control Programme (NASCP). The revenue model combines upfront meter sales (bundled with 25 free strips) with recurring revenue from strip refills, and international donor procurement for HIV RDTs.
Colexa Biosensor firmographics
Firmographics- Name
- Colexa Biosensor
- Legal name
- Colexa Biosensor Ltd
- Website
- https://colexabiosensor.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Colexa Biosensor Ltd is a Nigerian in-vitro diagnostics manufacturer that produces the OnPoint blood glucose monitoring system and locally packages the WHO pre-qualified STANDARD Q HIV rapid diagnostic test, serving the Nigerian Federal Government, state health programs, healthcare providers, and Sub-Saharan African consumer and donor markets.
- Ownership category
- akta.pro rank
Colexa Biosensor industry classification
Industry- Product category
- In-Vitro Diagnostics (IVD) Medical Devices
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
Keywords
Where Colexa Biosensor is headquartered
LocationHeadquarters
- HQ city
- Lagos
- HQ country
- Nigeria
- HQ region
- Africa
Offices3 records
Markets served
Colexa Biosensor business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Blood Glucose Monitoring Products: Sale of OnPoint blood glucose meters and test strips to healthcare providers, pharmacies, and directly to consumers. Meters sold with 25 free strips; recurring revenue from strip refills.
- WHO Pre-qualified HIV RDT Products: Local packaging and distribution of WHO pre-qualified HIV rapid diagnostic tests for national health programs and international donor procurement.
- E-commerce Retail Sales: Direct consumer sales through online store winwell.ng for blood glucose monitoring products.
Go-to-market motion2 records
Distribution channels6 records
Marketing channels7 records
Colexa Biosensor product offering
Product offeringCore offering
Colexa Biosensor manufactures and distributes the OnPoint GH82 Blood Glucose Monitoring System (meter and test strips) — Nigeria's first locally manufactured blood glucose monitoring solution — and packages the WHO pre-qualified STANDARD Q HIV 1/2 Ab 3-Line Test, being the only facility in Africa authorized to package a WHO pre-qualified HIV rapid diagnostic test. Products serve people living with diabetes, healthcare providers, government health programs, and international donor organizations.
Product overview
Colexa Biosensor is Nigeria and Sub-Saharan Africa's foremost in-vitro diagnostics manufacturer, producing a focused portfolio of diagnostic medical devices. The core offering consists of the OnPoint GH82 Blood Glucose Monitoring System (meter and strips), which represents Africa's first locally manufactured blood glucose monitoring solution, and the WHO pre-qualified STANDARD Q HIV 1/2 Ab 3-Line Test, which Colexa packages locally under WHO authorization. The company operates manufacturing facilities in Lagos and Sagamu, Nigeria, with an installed capacity of 3.6 million packs of strips annually, scalable to 10.8 million.
Differentiator
Problem solved
Functional benefit
Brands
- OnPoint: Nigeria's first locally manufactured blood glucose monitoring system including GH82 Blood Glucose Meter and Test Strips for diabetes management.
- Codeline
Products and services
- OnPoint GH82 Blood Glucose Monitoring System First locally manufactured blood glucose meter in Africa. Uses FAD glucose dehydrogenase (GDH) enzyme system for accurate readings. Features auto-coding, 6-second test time, strip ejector function, alarm reminders, and calculates 7/14/30-day averages. Provides results in both mmol/L and mg/dL units. Includes 2-year warranty with lifetime technical support. For use by people living with diabetes and healthcare professionals.
- OnPoint GH82 Blood Glucose Test Strip Quantitative measurement of glucose in fresh capillary whole blood samples from fingertips, palm, and forearm. For use with OnPoint GH82 meter. Single-use only strips with 6-month shelf life after opening vial. Enables daily self-monitoring of blood glucose for people living with diabetes.
- STANDARD Q HIV 1/2 Ab 3-Line Test Rapid chromatographic immunoassay for qualitative detection of antibodies specific to HIV-1 (including subtype O) and HIV-2 in human serum, plasma, or venous and capillary whole blood. Test time 10-20 minutes. High sensitivity (99.01-100%) and specificity (99.92-100%) across specimen types. Colexa Biosensor is the only facility in Africa authorized to package this WHO pre-qualified test. For use by national HIV testing programs, healthcare providers, and international donor organizations.
Quantifiable outcome
- Federal Government procurement of OnPoint blood glucose monitoring systems for distribution across primary healthcare centers nationwide
- +2 more outcomes
Companies that use Colexa Biosensor
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Colexa Biosensor technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Colexa Biosensor partnerships and signals
Strategic signalScale indicators8 records
Recent moves8 records
Expansion highlights6 records
Colexa Biosensor competitors and assessment
Company assessmentDirect peers
- Ascensia Diabetes Care: Specialist BGM company marketing the Contour portfolio of meters and strips. Direct peer focused exclusively on blood glucose monitoring for diabetes management, with comparable consumer/HCP positioning to Colexa.
- ARKRAY: Japanese manufacturer specializing in blood glucose monitoring devices and diabetes diagnostics. Comparable as a focused BGM manufacturer serving both consumer and clinical markets globally, including emerging markets.
- LifeScan (OneTouch): Pure-play blood glucose monitoring company behind OneTouch meters and strips. Direct competitor in BGM category with similar focus on affordable consumer and clinical glucose testing; comparable product specifications and target use cases to OnPoint.
- Bionime Corporation: Taiwan-based manufacturer of blood glucose monitoring systems with proprietary electrode technology. Comparable mid-sized specialist competing in the same BGM category with a focus on affordability and emerging market distribution.
- SD Biosensor: Korea-based IVD company whose STANDARD Q HIV 1/2 Ab 3-Line Test is licensed to Colexa for local packaging under WHO PQ. Direct partner and peer in rapid diagnostics, with global distribution of WHO-prequalified HIV, malaria, and hepatitis RDTs.
- ACON Laboratories: U.S.-based diagnostics manufacturer producing blood glucose meters, test strips, and rapid diagnostic tests. Comparable as a multi-IVD player with both BGM and RDT portfolios, including HIV and infectious disease tests distributed in Africa.
Broad incumbents
- Abbott Diabetes Care: Markets FreeStyle blood glucose meters and is the dominant player in consumer CGM via FreeStyle Libre. Comparable to Colexa in BGM category but vastly larger, with broader diabetes portfolio and aggressive expansion of CGM into emerging markets.
- Trinity Biotech: Ireland-based IVD company with a portfolio spanning diabetes (hemoglobin A1c), infectious disease, and clinical chemistry. Comparable as a publicly-traded specialist IVD manufacturer with global distribution reach across similar end-markets.
- Roche Diabetes Care: Global leader in blood glucose monitoring through the Accu-Chek brand, with deep clinical evidence and multinational distribution. Directly competes with Colexa's OnPoint in Nigeria and West Africa, but operates as part of a much broader diagnostics and pharma portfolio.
Emerging players
- Nova Biomedical: U.S.-based manufacturer of blood glucose and critical care analyzers for hospital and point-of-care use. Comparable in the BGM and POCT categories with technology overlap, but focused more on the clinical/professional segment than the consumer market Colexa targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Colexa Biosensor social profiles
Digital presenceColexa Biosensor compliance and trust
Trust signalCompliance2 records
Colexa Biosensor financial estimates
Financial estimateRevenue estimate
Valuation estimate
Colexa Biosensor leadership team
Management profileNumber of profiles
Profiles5 records
Colexa Biosensor funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Colexa Biosensor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Colexa Biosensor
What does Colexa Biosensor do?
Colexa Biosensor manufactures and distributes the OnPoint GH82 Blood Glucose Monitoring System (meter and test strips) — Nigeria's first locally manufactured blood glucose monitoring solution — and packages the WHO pre-qualified STANDARD Q HIV 1/2 Ab 3-Line Test, being the only facility in Africa authorized to package a WHO pre-qualified HIV rapid diagnostic test. Products serve people living with diabetes, healthcare providers, government health programs, and international donor organizations.
Is Colexa Biosensor a public or private company?
Colexa Biosensor is a private company. It is classified as corporate owned and is currently operating.
When was Colexa Biosensor founded?
Colexa Biosensor was founded in 2023. It employs 101 to 250 people.
Where is Colexa Biosensor based?
Colexa Biosensor is headquartered in Lagos, Nigeria, in the Africa region.
How does Colexa Biosensor make money?
Three revenue lines are on record. Blood Glucose Monitoring Products are the primary driver. The others are WHO Pre-qualified HIV RDT Products and E-commerce Retail Sales.
Who are Colexa Biosensor's main competitors?
Direct peers on record are Ascensia Diabetes Care, ARKRAY, LifeScan (OneTouch), Bionime Corporation, SD Biosensor and ACON Laboratories. Broad incumbents are Abbott Diabetes Care, Trinity Biotech and Roche Diabetes Care. Nova Biomedical is listed as an emerging player.
Does Colexa Biosensor have an API?
No public API is recorded for Colexa Biosensor.
What industry is Colexa Biosensor in?
Colexa Biosensor's product category is In-Vitro Diagnostics (IVD) Medical Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 325413 and its SIC code is 2835.